Search

Your search keyword '"Sigari, Naseh"' showing total 27 results
Start Over Author "Sigari, Naseh"
27 results on '"Sigari, Naseh"'

5. The risk profile of patients with COVID-19 as predictors of lung lesions severity and mortality-Development and validation of a prediction model

Author

Biostatistiek Onderzoek, Cancer, Data Science & Biostatistiek, RWE/Causal inference, Child Health, Rahimi, Ezat, Shahisavandi, Mina, Royo, Albert Cid, Azizi, Mohammad, El Bouhaddani, Said, Sigari, Naseh, Sturkenboom, Miriam, Ahmadizar, Fariba, Biostatistiek Onderzoek, Cancer, Data Science & Biostatistiek, RWE/Causal inference, Child Health, Rahimi, Ezat, Shahisavandi, Mina, Royo, Albert Cid, Azizi, Mohammad, El Bouhaddani, Said, Sigari, Naseh, Sturkenboom, Miriam, and Ahmadizar, Fariba

Published
2022

6. Diagnostic utility of adenosine deaminase in serum and bronchoalveolar lavage fluid for screening lung cancer in Western Iran

Author

Nikkhoo Bahram, Sigari Naseh, Ghaderi Bayazid, Afkhamzadeh Abdolrahim, Azadi Namam-Ali, Mohsenpour Behzad, Fathi Fardin, and Abdi Mohammad

Subjects
adenosine deaminase, lung cancer, serum, bronchoalveolar lavage, diagnostic value, Biochemistry, QD415-436
Abstract

Background: This study aimed to determine adenosine deaminase (ADA) activity as a possible screening tool in lung cancer patients. Methods: Blood samples were collected from 30 subjects with positive pathological tests and 62 patients with negative pathological tests as a control group. The enzymatic activity of total ADA and its isoenzymes was determined. Results: tADA and ADA2 isoenzyme activity was significantly higher in cancerous patients compared to benign controls in serum and BAL fluid. Using a cut-off level of respectively 35.22 U/L and 31.80 U/L for BAL total ADA and ADA2, sensitivity and specificity were 100% and 81% for total ADA and 95% and 98% for ADA2. Conclusions: Adenosine deaminase may play important roles in the pathophysiology of lung cancer and because of its might be considered as a useful screening tool among the other markers in lung cancer diagnosis.

Published
2013

8. Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease

Author

Smid, Dionne E., Franssen, Frits M.E., Gonik, Maria, Miravitlles, Marc, Casanova, Ciro, Cosio, Borja G., de Lucas-Ramos, Pilar, Marin, Jose M., Martinez, Cristina, Mir, Isabel, Soriano, Joan B., de Torres, Juan P., Agusti, Alvar, Atalay, Nart B., Billington, Julia, Boutou, Afroditi K., Brighenti-Zogg, Stefanie, Chaplin, Emma, Coster, Samantha, Dodd, James W., Dürr, Selina, Fernandez-Villar, Alberto, Groenen, Miriam T.J., Guimarães, Miguel, Hejduk, Karel, Higgins, Victoria, Hopkinson, Nicholas S., Horita, Nobuyuki, Houben-Wilke, Sarah, Janssen, Daisy J.A., Jehn, Melissa, Joerres, Rudolf, Karch, Annika, Kelly, Julia L., Kim, Yu-Il, Kimura, Hiroshi, Koblizek, Vladimir, Kocks, Janwillem H., Kon, Samantha S.C., Kwon, Namhee, Ladeira, Inês, Lee, Sang-Do, Leuppi, Joerg D., Locantore, Nicholas, Lopez-Campos, José L., D-C Man, William, Maricic, Lana, Mendoza, Laura, Miedinger, David, Mihaltan, Florin, Minami, Seigo, van der Molen, Thys, Murrells, Trevor J., Nakken, Nienke, Nishijima, Yu, Norman, Ian J., Novotna, Barbora, O'Donnell, Denis E., Ogata, Yoshitaka, Pereira, Eanes D., Piercy, James, Price, David, Pothirat, Chaicharn, Raghavan, Natya, Ringbaek, Thomas, Sajkov, Dimitar, Sigari, Naseh, Singh, Sally, Small, Mark, da Silva, Guilherme F., Tanner, Rebecca J., Tsiligianni, Ioanna G., Tulek, Baykal, Tzanakis, Nikolaos, Vanfleteren, Lowie E.G.W., Watz, Henrik, Webb, Katherine A., Wouters, Emiel F.M., Xie, Guogang G., Yoshikawa, Masanori, and Spruit, Martijn A.

Published
2017
Full Text
View/download PDF

10. Comparative efficacy of honey 12.5% and chlorhexidine 0.2% mouthwashes on the oropharyngeal bacterial colonization in mechanically-ventilated patients: a randomized controlled trial

Author

Amiri, Halimeh, Ramezani-Badr, Farhad, Sigari, Naseh, and Nasseri, Karim

Subjects
Adult, Male, Mouth, Bacteria, Microbiota, Chlorhexidine, Mouthwashes, Oropharynx, Pneumonia, Ventilator-Associated, Honey, Middle Aged, Respiration, Artificial, Young Adult, Humans, Female, Single-Blind Method, Aged
Abstract

To compare the efficacy of honey mouthwash 12.5% and chlorhexidine solution 0.2% to reduce the rate of oropharyngeal bacterial colonization in mechanically-ventilated patients.This study was a randomized, single blind, phase Ⅲ controlled clinical trial. Sixty patients newly admitted to internal and trauma Intensive Care Units of the two educational hospitals of Sanandaj city affiliated with Kurdistan University of Medical Sciences were selected by convenience sampling and allocated to two groups of 30 patients using random blocks design. In each group, the mouthwash was applied twice a day for four consecutive days. Swab samples were taken from the mouth and throat of all patients three times a day (pre- intervention, two days, and four days after the intervention) and then the samples were transferred onto the blood agar and eosin methylene blue (EMB) culture plates and investigated for bacterial growth and colonization after 24-48 h.The findings showed that oropharyngeal colonization was not significantly different between the two groups, pre-intervention, two days, and four days after the intervention (P0.05). Rinsing with honey mouthwash 12.5% led to the inhibition of Staphylococcus aureus and Pseudomonas aeruginosa on the fourth day of the intervention in all samples.None of the studied solutions contributed to the reduction of oropharyngeal bacterial colonization. It seems that the growth inhibition of Staphylococcus aureus and Pseudomonas aeruginosa by the honey 12.5% mouthwash in mechanically-ventilated patients need further investigation.

Published
2020

11. Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease

Author

Smid, Dionne E., Gonik, Maria, Atalay, Nart Bedin, Raghavan, Natya, Pothirat, Chaicharn, Price, David, Piercy, James, Miravitlles, Marc, Casanova, Ciro, Pereira, Eanes D., Ogata, Yoshitaka, O'Donnell, Denis E., Novotna, Barbora, Norman, Ian J., Nishijima, Yu, Nakken, Nienke, Murrells, Trevor J., van der Molen, Thys, Minami, Seigo, Mihaltan, Florin, Miedinger, David, Mendoza, Laura, Maricic, Lana, Man, William D-C, Lopez-Campos, Jose L., Franssen, Frits M. E., Ringbaek, Thomas, Soriano, Joan B., Locantore, Nicholas, Leuppi, Joerg D., Sajkov, Dimitar, Lee, Sang-Do, Ladeira, Ines, Cosio, Borja G., Kwon, Namhee, Mir, Isabel, Martinez, Cristina, Kon, Samantha S. C., Kocks, Janwillem H., Koblizek, Vladimir, Kimura, Hiroshi, Kim, Yu-Il, Kelly, Julia L., Karch, Annika, Joerres, Rudolf, Jehn, Melissa, Janssen, Daisy J. A., Houben-Wilke, Sarah, Sigari, Naseh, Horita, Nobuyuki, Hopkinson, Nicholas S., Higgins, Victoria, Singh, Sally, Small, Mark, Hejduk, Karel, Guimaraes, Miguel, Groenen, Miriam T. J., Fernandez-Villar, Alberto, Durr, Selina, Dodd, James W., Coster, Samantha, Chaplin, Emma, Brighenti-Zogg, Stefanie, Boutou, Afroditi K., Billington, Julia, Agusti, Alvar, de Torres, Juan P., da Silva, Guilherme F., Tanner, Rebecca J., Tsiligianni, Ioanna G., Marin, Jose M., de Lucas-Ramos, Pilar, Tülek, Baykal, Tzanakis, Nikolaos, Vanfleteren, Lowie E. G. W., Spruit, Martijn A., Watz, Henrik, Yoshikawa, Masanori, Webb, Katherine A., Xie, Guogang G., Wouters, Emiel F. M., Smid, Dionne E., Gonik, Maria, Atalay, Nart Bedin, Raghavan, Natya, Pothirat, Chaicharn, Price, David, Piercy, James, Miravitlles, Marc, Casanova, Ciro, Pereira, Eanes D., Ogata, Yoshitaka, O'Donnell, Denis E., Novotna, Barbora, Norman, Ian J., Nishijima, Yu, Nakken, Nienke, Murrells, Trevor J., van der Molen, Thys, Minami, Seigo, Mihaltan, Florin, Miedinger, David, Mendoza, Laura, Maricic, Lana, Man, William D-C, Lopez-Campos, Jose L., Franssen, Frits M. E., Ringbaek, Thomas, Soriano, Joan B., Locantore, Nicholas, Leuppi, Joerg D., Sajkov, Dimitar, Lee, Sang-Do, Ladeira, Ines, Cosio, Borja G., Kwon, Namhee, Mir, Isabel, Martinez, Cristina, Kon, Samantha S. C., Kocks, Janwillem H., Koblizek, Vladimir, Kimura, Hiroshi, Kim, Yu-Il, Kelly, Julia L., Karch, Annika, Joerres, Rudolf, Jehn, Melissa, Janssen, Daisy J. A., Houben-Wilke, Sarah, Sigari, Naseh, Horita, Nobuyuki, Hopkinson, Nicholas S., Higgins, Victoria, Singh, Sally, Small, Mark, Hejduk, Karel, Guimaraes, Miguel, Groenen, Miriam T. J., Fernandez-Villar, Alberto, Durr, Selina, Dodd, James W., Coster, Samantha, Chaplin, Emma, Brighenti-Zogg, Stefanie, Boutou, Afroditi K., Billington, Julia, Agusti, Alvar, de Torres, Juan P., da Silva, Guilherme F., Tanner, Rebecca J., Tsiligianni, Ioanna G., Marin, Jose M., de Lucas-Ramos, Pilar, Tülek, Baykal, Tzanakis, Nikolaos, Vanfleteren, Lowie E. G. W., Spruit, Martijn A., Watz, Henrik, Yoshikawa, Masanori, Webb, Katherine A., Xie, Guogang G., and Wouters, Emiel F. M.

Abstract

Background: Patients with chronic obstructive pulmonary disease (COPD) can be classified into groups A/C or B/D based on symptom intensity. Different threshold values for symptom questionnaires can result in misclassification and, in turn, different treatment recommendations. The primary aim was to find the best fitting cut-points for Global initiative for chronic Obstructive Lung Disease (GOLD) symptom measures, with an modified Medical Research Council dyspnea grade of 2 or higher as point of reference. Methods: After a computerized search, data from 41 cohorts and whose authors agreed to provide data were pooled. COPD studies were eligible for analyses if they included, at least age, sex, post-bronchodilator spirometry, modified Medical Research Council, and COPD Assessment Test (CAT) total scores. Main outcomes: Receiver operating characteristic curves and the Youden index were used to determine the best calibration threshold for CAT, COPD Clinical Questionnaire, and St. Georges Respiratory Questionnaire total scores. Following, GOLD A/B/C/D frequencies were calculated based on current cut-points and the newly derived cut-points. Findings: A total of 18,577 patients with COPD [72.0% male; mean age: 66.3 years (standard deviation 9.6)] were analyzed. Most patients had a moderate or severe degree of airflow limitation (GOLD spirometric grade 1, 10.9%; grade 2, 46.6%; grade 3, 32.4%; and grade 4, 10.3%). The best calibration threshold for CAT total score was 18 points, for COPD Clinical Questionnaire total score 1.9 points, and for St. Georges Respiratory Questionnaire total score 46.0 points. Conclusions: The application of these new cut-points would reclassify about one-third of the patients with COPD and, thus, would impact on individual disease management. Further validation in prospective studies of these new values are needed. (C) 2017 AMDA - The Society for Post-Acute and Long-Term Care Medicine.

Published
2019

12. Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease

Author

Hopkinson, Nicholas S., Sajkov, Dimitar, Maricic, Lana, Man, William D-C, Lopez-Campos, Jose L., Locantore, Nicholas, Leuppi, Joerg D., Lee, Sang-Do, Ladeira, Ines, Kwon, Namhee, Kon, Samantha S. C., Kocks, Janwillem H., Wouters, Emiel F. M., Koblizek, Vladimir, Casanova, Ciro, Gonik, Maria, Miravitlles, Marc, Xie, Guogang G., de Lucas-Ramos, Pilar, Yoshikawa, Masanori, Spruit, Martijn A., Marin, Jose M., Martinez, Cristina, Kimura, Hiroshi, Mir, Isabel, Soriano, Joan B., Kim, Yu-Il, Kelly, Julia L., Karch, Annika, Joerres, Rudolf, Jehn, Melissa, de Torres, Juan P., Janssen, Daisy J. A., Agusti, Alvar, Billington, Julia, Houben-Wilke, Sarah, Boutou, Afroditi K., Brighenti-Zogg, Stefanie, Chaplin, Emma, Coster, Samantha, Dodd, James W., Durr, Selina, Atalay, Nart Bedin, Fernandez-Villar, Alberto, Groenen, Miriam T. J., Guimaraes, Miguel, Hejduk, Karel, Higgins, Victoria, Horita, Nobuyuki, Sigari, Naseh, Singh, Sally, Small, Mark, Tsiligianni, Ioanna G., da Silva, Guilherme F., Ringbaek, Thomas, Tanner, Rebecca J., Smid, Dionne E., Raghavan, Natya, Cosio, Borja G., Pothirat, Chaicharn, Price, David, Piercy, James, Tülek, Baykal, Tzanakis, Nikolaos, Pereira, Eanes D., Ogata, Yoshitaka, O'Donnell, Denis E., Novotna, Barbora, Norman, Ian J., Nishijima, Yu, Nakken, Nienke, Murrells, Trevor J., van der Molen, Thys, Minami, Seigo, Franssen, Frits M. E., Mihaltan, Florin, Vanfleteren, Lowie E. G. W., Watz, Henrik, Webb, Katherine A., Miedinger, David, Mendoza, Laura, Hopkinson, Nicholas S., Sajkov, Dimitar, Maricic, Lana, Man, William D-C, Lopez-Campos, Jose L., Locantore, Nicholas, Leuppi, Joerg D., Lee, Sang-Do, Ladeira, Ines, Kwon, Namhee, Kon, Samantha S. C., Kocks, Janwillem H., Wouters, Emiel F. M., Koblizek, Vladimir, Casanova, Ciro, Gonik, Maria, Miravitlles, Marc, Xie, Guogang G., de Lucas-Ramos, Pilar, Yoshikawa, Masanori, Spruit, Martijn A., Marin, Jose M., Martinez, Cristina, Kimura, Hiroshi, Mir, Isabel, Soriano, Joan B., Kim, Yu-Il, Kelly, Julia L., Karch, Annika, Joerres, Rudolf, Jehn, Melissa, de Torres, Juan P., Janssen, Daisy J. A., Agusti, Alvar, Billington, Julia, Houben-Wilke, Sarah, Boutou, Afroditi K., Brighenti-Zogg, Stefanie, Chaplin, Emma, Coster, Samantha, Dodd, James W., Durr, Selina, Atalay, Nart Bedin, Fernandez-Villar, Alberto, Groenen, Miriam T. J., Guimaraes, Miguel, Hejduk, Karel, Higgins, Victoria, Horita, Nobuyuki, Sigari, Naseh, Singh, Sally, Small, Mark, Tsiligianni, Ioanna G., da Silva, Guilherme F., Ringbaek, Thomas, Tanner, Rebecca J., Smid, Dionne E., Raghavan, Natya, Cosio, Borja G., Pothirat, Chaicharn, Price, David, Piercy, James, Tülek, Baykal, Tzanakis, Nikolaos, Pereira, Eanes D., Ogata, Yoshitaka, O'Donnell, Denis E., Novotna, Barbora, Norman, Ian J., Nishijima, Yu, Nakken, Nienke, Murrells, Trevor J., van der Molen, Thys, Minami, Seigo, Franssen, Frits M. E., Mihaltan, Florin, Vanfleteren, Lowie E. G. W., Watz, Henrik, Webb, Katherine A., Miedinger, David, and Mendoza, Laura

Abstract

Background: Patients with chronic obstructive pulmonary disease (COPD) can be classified into groups A/C or B/D based on symptom intensity. Different threshold values for symptom questionnaires can result in misclassification and, in turn, different treatment recommendations. The primary aim was to find the best fitting cut-points for Global initiative for chronic Obstructive Lung Disease (GOLD) symptom measures, with an modified Medical Research Council dyspnea grade of 2 or higher as point of reference. Methods: After a computerized search, data from 41 cohorts and whose authors agreed to provide data were pooled. COPD studies were eligible for analyses if they included, at least age, sex, post-bronchodilator spirometry, modified Medical Research Council, and COPD Assessment Test (CAT) total scores. Main outcomes: Receiver operating characteristic curves and the Youden index were used to determine the best calibration threshold for CAT, COPD Clinical Questionnaire, and St. Georges Respiratory Questionnaire total scores. Following, GOLD A/B/C/D frequencies were calculated based on current cut-points and the newly derived cut-points. Findings: A total of 18,577 patients with COPD [72.0% male; mean age: 66.3 years (standard deviation 9.6)] were analyzed. Most patients had a moderate or severe degree of airflow limitation (GOLD spirometric grade 1, 10.9%; grade 2, 46.6%; grade 3, 32.4%; and grade 4, 10.3%). The best calibration threshold for CAT total score was 18 points, for COPD Clinical Questionnaire total score 1.9 points, and for St. Georges Respiratory Questionnaire total score 46.0 points. Conclusions: The application of these new cut-points would reclassify about one-third of the patients with COPD and, thus, would impact on individual disease management. Further validation in prospective studies of these new values are needed. (C) 2017 AMDA - The Society for Post-Acute and Long-Term Care Medicine.

Published
2019

14. Anti-citrullinated peptide antibodies in rheumatoid arthritis patients exposed to wood smoke.

Author

Moghimi, Nasrin, Sigari, Naseh, Hosinian, Sayed Mohammad, Saeedi, Afshin, Roshani, Daem, Moshref, Mohammad Ali Zeinolabedin, Nourbakhsh, Shirin, and Babahajian, Asrin

Subjects
*RHEUMATOID factor, *RHEUMATOID arthritis, *BLOOD sedimentation, *SMOKE, *IMMUNOGLOBULINS, *AUTOIMMUNE diseases
Abstract

Background and Aims: Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune disease with an unknown etiology, which attacks the synovial tissue more than any other organ. Citrulline has been observed in the joints of RA patients. Anti-citrullinated peptide antibodies (ACPAs), which are recognized as the most specific serologic markers of RA, are synthesized against unusual citrullinated peptides during the disease. There is little information about the increased production of antibodies against citrullinated peptides in RA patients exposed to wood smoke. Therefore, in this study, we aimed to compare the serum level of ACPA in two groups of exposed and non-exposed RA patients to wood smoke. Materials and Methods: A total of 110 RA patients, including 55 exposed patients to wood smoke and 55 non-exposed patients, were enrolled in this study. The serum level of ACPA, rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), and disease activity (based on the 28-joint Disease Activity Score) were determined in patients and compared between the two groups. Results: In this study, there was no significant difference in the serum level of ACPA between the exposed and non-exposed groups (P = 0.73). On the other hand, RF (P = 0.03), ESR (P = 0.007), and disease activity index (P = 0.01) were significantly higher in the exposed group, compared to the non-exposed group. Conclusion: According to the results of the current study, pollutants from wood smoke significantly increased the RF, ESR, and disease activity index in RA patients. Nonetheless, there was no significant difference in the serum level of ACPA between the two groups. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

15. Validation of Persian Version of Asthma Control Test Based on new Global Initiative for Asthma Guidelines

Author

Sigari, Naseh, Sigari, Nader, Ghasri, Hooman, Rahimi, Ezzat, and Mohammadi, Shilan

Subjects
Original Article, Asthma control test, Guideline, Asthma, respiratory tract diseases
Abstract

Background Asthma is a serious global health problem. The lack of a clinical gold standard for evaluation of asthma control, as well as inadequate recognition of uncontrolled asthma by patients and clinicians may contribute to this situation. The Asthma Control Test is an easy and reliable test. The aim of this study was to validate the Persian version of this test with regard to GINA2009 guidelines based on a specialist's rating of asthma control. Materials and Methods Patients (n = 150) completed the Asthma Control Test. Pulmonary function was measured. A chest specialist rated asthma control in line with the Global Initiative for Asthma 2009 guidelines. Patients were divided into well controlled, partly controlled and uncontrolled groups in order to evaluate the reliability and validity of the ACT. Results The mean age was 41.68 years. The internal consistency reliability of 5-item ACT survey was 0.89%. There were no significant differences in ACT scores between different age, gender, educational status and inhabitancy groups. Between the groups with different GINA-based control levels, a significant difference in ACT score was noted in favor of an ACT-based discrimination of different states of asthma control (F = 305.3, P < 0.001). Patient group with poorer lung function (FEV1) scored significantly lower on the ACT than groups with better lung function (F = 6.82, P < 0.001). Differences in ACT score between treatment recommendation groups were significant (F = 50.54, P < 0.001). Statistically significant correlations were observed between ACT scores and GINA-based values of asthma control rating by a specialist (r = 0.86, p < 0.001) and treatment recommendations (r = 0.54, p < 0.001). Correlation between ACT score and percentage of FEV1 predicted was moderate (r = 0.39, P < 0.001). Conclusion The Persian version of Asthma Control Test is a valid and reliable test for asthma control assessment.

Published
2011

16. Comparative Network Analysis of Patients with Non-Small Cell Lung Cancer and Smokers for Representing Potential Therapeutic Targets

Author

Pazhouhandeh, Mehrdad, primary, Samiee, Fatemeh, additional, Boniadi, Tahereh, additional, Khedmat, Abbas Fadaei, additional, Vahedi, Ensieh, additional, Mirdamadi, Mahsa, additional, Sigari, Naseh, additional, Siadat, Seyed Davar, additional, Vaziri, Farzam, additional, Fateh, Abolfazl, additional, Ajorloo, Faezeh, additional, Tafsiri, Elham, additional, Ghanei, Mostafa, additional, Mahboudi, Fereidoun, additional, and Rahimi Jamnani, Fatemeh, additional

Published
2017
Full Text
View/download PDF

19. What Do We Know about Anthracofibrosis? A Literature Review.

Author

Jamaati, Hamdireza, Sharifi, Amirsina, Mirenayat, Maryam Sadat, Mirsadraee, Majid, Amoli, Kazem, Heidarnazhad, Hassan, Sigari, Naseh, Saeedfar, Kayvan, Kahkouee, Shahram, Toutkaboni, Mihan Pourabdollah, Mortaz, Esmaeel, Hashemian, Seyed Mohammadreza, and Mohamadnia, Abdolreza

Subjects
PULMONARY fibrosis, DUST diseases, BRONCHIAL diseases
Abstract

Recently, the significance of anthracosis in the tracheobronchial tree, lung parenchyma, and even non-respiratory organs has been postulated and discussed in association with other diseases, especially tuberculosis. We reviewed the current literature by using the following key words in Medline/PubMed, Embase, and Google Scholar databases: anthracosis, anthracofibrosis, anthracotic bronchitis, biomass fuels, and mixed-dust pneumoconiosis. The bibliographies of eligible papers were also reviewed for further relevant articles. A total of 37 studies were assessed. The content of these studies was then divided into specific categories. Considering the pathogenesis, along with histopathological, radiological, and bronchoscopic results regarding anthracotic lesions, we suggest these findings be defined as "ANTHRACOSIS SYNDROME". For the first time, we describe a syndrome involving black pigmentation, which was previously thought to involve only the tracheobronchial tree. Until recently, it was not considered to be a single syndrome with different sites of involvement. [ABSTRACT FROM AUTHOR]

Published
2017

22. Correlation between hs-CRP and Asthma Control Indices.

Author

Sigari, Naseh and Ghasri, Hooman

Subjects
*ANTIASTHMATIC agents, *RESPIRATORY allergy, *ASTHMA, *PULMONARY function tests, *CHRONICALLY ill
Abstract

Background: Local and systemic inflammation occur at the same time in asthma and high sensitive CRP may play a role in the pathogenesis of this disease. Conventional approaches to monitor and control asthma involve no direct assessment of airway inflammation. There are some recent data postulating a discrepancy between the markers of airway and systemic inflammation and asthma control test (ACT) scores. In this study we evaluate the correlation between the serum levels of hs- CRP in patients with different levels of asthma control based on ACT scores and spirometric indices. Materials and Methods: The validated Persian version of ACT was administered to one-hundred asthmatic patients. Spirometry was performed and prebronchodilatory FEV1 was measured. Blood samples for CRP measurement were taken and hs-CRP levels were analyzed. Fifty age- matched healthy volunteers comprised the control group. Results: A total of 100 asthmatic patients (57 females and 43 males) and 50 controls were participated. hs-CRP in asthmatics was higher than in controls. No significant differences were found in hs-CRP levels in patients with different levels of asthma control based on ACT (⩾20, 16-19, ⩽15), GINA classification of asthma control (well controlled, partly controlled, uncontrolled) or FEV1. Conclusion: We found no correlation between degree of systemic inflammation estimated by hs-CRP and other clinical indices of asthma control such as ACT scores, FEV1 and GINA classification of asthma control and even in patients with clinical and spirometric indices of controlled asthma, markers of systemic inflammation were still present. [ABSTRACT FROM AUTHOR]

Published
2013

23. Diagnostic value of serum adenosine deaminase level in pulmonary tuberculosis.

Author

Afrasiabian, Shahla, Mohsenpour, Behzad, Bagheri, Katayoun Haji, Sigari, Naseh, and Aftabi, Kaveh

Subjects
TUBERCULOSIS diagnosis, TUBERCULOSIS mortality, ADENOSINES, CONFIDENCE intervals, ENZYMES, IMMUNITY, MEDICAL care, PATIENTS, SERIAL publications, SPUTUM, DATA analysis, CROSS-sectional method
Abstract

BACKGROUND: In some studies, the level of adenosine deaminase (ADA) in sputum and effusion liquids was used for the diagnosis of tuberculosis (TB). But it is not always possible to access these materials. The goal of this study is to assess the diagnostic value of serum ADA levels in pulmonary TB patients. MATERIALS AND METHODS: In this study, 40 sputum smear-positive TB patients who were hospitalized and 40 non-TB patients who referred for surgeries were selected. A serum sample was collected and serum ADA level was measured by ADA kit. RESULTS: The average (SD) of serum ADA in TB and non-TB patients were 20.88 (±5.97) and 10.69 (±2.98) U/L, respectively (P value < 0.05). The best cut-off point was 14 U/L. The calculated area under the receiver operating characteristic (ROC) curve was 0.955 (95% CI, 0.914-0.995); sensitivity was 92.7% (95% CI, 84.7-100) and specificity was 88.1% (95% CI, 78.3-97.8) (P < 0.001). CONCLUSION: Serum ADA level may be proposed as a proper index for TB diagnosis. [ABSTRACT FROM AUTHOR]

Published
2013

24. Reliability and Validity of Persian Version of Perceived Stress Scale (PSS-10) in Adults with Asthma.

Author

Maroufizadeh, Saman, Zareiyan, Armin, and Sigari, Naseh

Abstract

Background: Asthma is a major public health problem in the world, and recent findings suggest that stress influences asthma and asthma morbidity. The 10-item Perceived Stress Scale (PSS-10) is one of the most frequently used instruments to measure psychological stress. This study was conducted to evaluate the psychometric properties of the Persian versions of the PSS-10 in adults with asthma. Methods: In this descriptive cross-sectional study as a methodological research, 106 asthmatic patients referring to several clinics in Sanandaj (western Iran) were selected through convenience sampling. The PSS-10 and the 21-item Depression anxiety and stress scale (DASS-21) were administrated to all patients. Cronbach's alpha was used to evaluate reliability of PSS-10, and confirmatory factor analysis (CFA) and convergent validity were used to evaluate its validity. Results: The results of confirmatory factor analysis indicated that a two-factor structure of PSS-10 provided a good fit to data. The Cronbach's alpha coefficients for negative factor, positive factor and total score (PSS-10) were 0.86, 0.83, and 0.90, respectively. The PSS-10 was positively correlated with the DASS-21 and its subscales, indicating an acceptable convergent validity. Female asthmatic patients scored higher on PSS-10 in comparison with male asthmatic patients. Conclusion: The Persian version of PSS-10 is a valid and reliable instrument to measure perceived stress in adults with asthma. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

25. Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease

Author

Masanori Yoshikawa, Daisy J.A. Janssen, Selina Dürr, Rudolf Joerres, Julia Billington, Nicholas Locantore, Florin Mihaltan, Sally Singh, Dimitar Sajkov, Thys van der Molen, Borja G. Cosío, Guilherme F. da Silva, Sarah Houben-Wilke, Ian Norman, Baykal Tulek, Jose M. Marin, David Miedinger, Samantha Coster, Janwillem W. H. Kocks, Sang Do Lee, Karel Hejduk, Juan P. de Torres, Maria Gonik, Mark Small, Samantha S.C. Kon, Nobuyuki Horita, Katherine A. Webb, Naseh Sigari, Ioanna Tsiligianni, Natya Raghavan, Yoshitaka Ogata, William D.-C. Man, Afroditi K. Boutou, Cristina Martínez, Marc Miravitlles, Lowie E.G.W. Vanfleteren, Miriam T.J. Groenen, Barbora Novotna, Isabel Mir, Miguel Guimaraes, Alvar Agusti, Nart Bedin Atalay, Dionne E. Smid, Trevor Murrells, Stefanie Brighenti-Zogg, Henrik Watz, Seigo Minami, José Luis López-Campos, Frits M.E. Franssen, Nicholas S Hopkinson, Pilar de Lucas-Ramos, Emiel F.M. Wouters, James Piercy, Melissa Jehn, Emma Chaplin, Vladimir Koblizek, Ciro Casanova, Nikolaos Tzanakis, Rebecca Tanner, Hiroshi Kimura, Lana Maricic, Nienke Nakken, David Price, Alberto Fernández-Villar, Denis E. O'Donnell, Annika Karch, Martijn A. Spruit, Yu-Il Kim, Joan B. Soriano, Ines Ladeira, Yu Nishijima, Namhee Kwon, Victoria Higgins, Laura Mendoza, Eanes Delgado Barros Pereira, Julia L. Kelly, Thomas Ringbaek, Guogang G. Xie, Chaicharn Pothirat, James W. Dodd, Joerg D. Leuppi, RS: NUTRIM - R3 - Respiratory & Age-related Health, Pulmonologie, Afdeling Onderwijs FHML, RS: NUTRIM - R3 - Chronic inflammatory disease and wasting, Promovendi NTM, MUMC+: MA Longziekten (3), [Smid, Dionne E.] CIRO, Dept Res & Educ, Hornerheide 1, NL-6085 NM Horn, Netherlands, [Franssen, Frits M. E.] CIRO, Dept Res & Educ, Hornerheide 1, NL-6085 NM Horn, Netherlands, [Groenen, Miriam T. J.] CIRO, Dept Res & Educ, Hornerheide 1, NL-6085 NM Horn, Netherlands, [Houben-Wilke, Sarah] CIRO, Dept Res & Educ, Hornerheide 1, NL-6085 NM Horn, Netherlands, [Janssen, Daisy J. A.] CIRO, Dept Res & Educ, Hornerheide 1, NL-6085 NM Horn, Netherlands, [Nakken, Nienke] CIRO, Dept Res & Educ, Hornerheide 1, NL-6085 NM Horn, Netherlands, [Vanfleteren, Lowie E. G. W.] CIRO, Dept Res & Educ, Hornerheide 1, NL-6085 NM Horn, Netherlands, [Wouters, Emiel F. M.] CIRO, Dept Res & Educ, Hornerheide 1, NL-6085 NM Horn, Netherlands, [Spruit, Martijn A.] CIRO, Dept Res & Educ, Hornerheide 1, NL-6085 NM Horn, Netherlands, [Franssen, Frits M. E.] Maastricht Univ, Med Ctr, Dept Resp Med, Maastricht, Netherlands, [Vanfleteren, Lowie E. G. W.] Maastricht Univ, Med Ctr, Dept Resp Med, Maastricht, Netherlands, [Wouters, Emiel F. M.] Maastricht Univ, Med Ctr, Dept Resp Med, Maastricht, Netherlands, [Gonik, Maria] Biomax Informat AG, Planegg, Germany, [Miravitlles, Marc] Hosp Univ Hebron, CIBER Enfermedades Resp CIBERES, Pneumol Dept Hosp, Barcelona, Spain, [Casanova, Ciro] Hosp Univ NS Candelaria, Pulmonaty Dept, Santa Cruz de Tenerife, Spain, [Casanova, Ciro] Hosp Univ NS Candelaria, Res Unit, Santa Cruz de Tenerife, Spain, [Cosio, Borja G.] Hosp Son Espases IdISPa CIBERES, Dept Resp Med, Islas Baleares, Spain, [de Lucas-Ramos, Pilar] Hosp Gen Univ Gregorio Maranon, Pulm Dept, Madrid, Spain, [Marin, Jose M.] Hosp Univ Miguel Servet, IISAragon, CIBER Enfermedades Resp, Zaragoza, Spain, [Martinez, Cristina] Hosp Univ Cent Asturias, Inst Nacl Silicosis, Pneumol Serv, Oviedo, Spain, [Mir, Isabel] Hosp Gen Univ Gregorio Maranon, Pulm Dept, Madrid, Spain, [Soriano, Joan B.] Univ Autonoma Madrid, Hosp Univ Princesa, Inst Invest, IISP, Madrid, Spain, [de Torres, Juan P.] Clin Univ Navarra, Pulm Dept, Pamplona, Spain, [Agusti, Alvar] Univ Barcelona, Hosp Clin, Resp Inst, Barcelona, Spain, [Agusti, Alvar] CIBERES, Madrid, Spain, [Atalay, Nart B.] TOBB Univ Econ & Technol, Dept Psychol, Ankara, Turkey, [Billington, Julia] Surbiton Hlth Ctr, Cent Surg, Surrey, England, [Boutou, Afroditi K.] G Gennimats Gen Hosp, Intens Care Unit, Thessaloniki, Greece, [Boutou, Afroditi K.] Aristotle Univ Thessaloniki, Resp Failure Unit, Thessaloniki, Greece, [Brighenti-Zogg, Stefanie] Univ Clin Med, Cantonal Hosp Baselland, Liestal, Switzerland, [Durr, Selina] Univ Clin Med, Cantonal Hosp Baselland, Liestal, Switzerland, [Leuppi, Joerg D.] Univ Clin Med, Cantonal Hosp Baselland, Liestal, Switzerland, [Miedinger, David] Univ Clin Med, Cantonal Hosp Baselland, Liestal, Switzerland, [Chaplin, Emma] Univ Hosp Leicester NHS Trust, NIHR Leicester Resp Biomed Res Unit, Ctr Exercise & Rehabil Sci, Leicester, Leics, England, [Singh, Sally] Univ Hosp Leicester NHS Trust, NIHR Leicester Resp Biomed Res Unit, Ctr Exercise & Rehabil Sci, Leicester, Leics, England, [Coster, Samantha] Kings Coll London, Florence Nightingale Fac Nursing & Midwifery, London, England, [Murrells, Trevor J.] Kings Coll London, Florence Nightingale Fac Nursing & Midwifery, London, England, [Norman, Ian J.] Kings Coll London, Florence Nightingale Fac Nursing & Midwifery, London, England, [Dodd, James W.] Univ Bristol, Southmead Hosp Bristol, North Bristol Lung Ctr, Acad Resp Unit, Bristol, Avon, England, [Fernandez-Villar, Alberto] Complexo Hosp Vigo, Inst Invest Biomed Vigo, Serv Neumol, Pontevedra, Spain, [Guimaraes, Miguel] Ctr Hosp Vila Nova Gaia Espinho, Pulmonol Dept, Vila Nova De Gaia, Portugal, [Ladeira, Ines] Ctr Hosp Vila Nova Gaia Espinho, Pulmonol Dept, Vila Nova De Gaia, Portugal, [Hejduk, Karel] Masaryk Univ, Fac Med, Inst Biostat & Analyses, Brno, Czech Republic, [Higgins, Victoria] Adelphi Real World, Bollington, England, [Piercy, James] Adelphi Real World, Bollington, England, [Small, Mark] Adelphi Real World, Bollington, England, [Hopkinson, Nicholas S.] Imperial Coll London, Royal Brompton & Harefield NHS Fdn Trust, NIHR Resp Biomed Res Unit, London, England, [Tanner, Rebecca J.] Imperial Coll London, Royal Brompton & Harefield NHS Fdn Trust, NIHR Resp Biomed Res Unit, London, England, [Horita, Nobuyuki] Yokohama City Univ, Grad Sch Med, Dept Pulmonol, Yokohama, Kanagawa, Japan, [Jehn, Melissa] Charite Univ Med Berlin, Arbeitsbereich Ambulante Pneumol, Berlin, Germany, [Joerres, Rudolf] Inst & Output Clin Occupat & Environm Med, Munich, Germany, [Karch, Annika] Hannover Med Sch, Inst Biostat, Hannover, Germany, [Kelly, Julia L.] Imperial Coll London, NIHR Resp Dis Biomed Res Unit Royal Brompton, Natl Heart & Lung Inst, Acad Unit Sleep & Ventilat, London, England, [Kelly, Julia L.] Harefield NHS Fdn Trust & Imperial Coll, London, England, [Kim, Yu-Il] Chonnam Natl Univ Hosp, Dept Internal Med, Div Pulmonol, Donggu, Gwangju, South Korea, [Kimura, Hiroshi] Nara Med Univ, Dept Internal Med 2, Nara, Japan, [Yoshikawa, Masanori] Nara Med Univ, Dept Internal Med 2, Nara, Japan, [Koblizek, Vladimir] Charles Univ Prague, Fac Med Hradec Kralove, Dept Pneumol, Hradec Kralove, Czech Republic, [Novotna, Barbora] Charles Univ Prague, Fac Med Hradec Kralove, Dept Pneumol, Hradec Kralove, Czech Republic, [Koblizek, Vladimir] Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic, [Novotna, Barbora] Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic, [Kocks, Janwillem H.] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma, Dept Primary Care, Groningen, Netherlands, [van der Molen, Thys] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma, Dept Primary Care, Groningen, Netherlands, [Tsiligianni, Ioanna G.] Univ Groningen, Univ Med Ctr Groningen, Groningen Res Inst Asthma, Dept Primary Care, Groningen, Netherlands, [Kocks, Janwillem H.] Univ Groningen, Univ Med Ctr Groningen, GRIAC, COPD, Groningen, Netherlands, [van der Molen, Thys] Univ Groningen, Univ Med Ctr Groningen, GRIAC, COPD, Groningen, Netherlands, [Tsiligianni, Ioanna G.] Univ Groningen, Univ Med Ctr Groningen, GRIAC, COPD, Groningen, Netherlands, [Kon, Samantha S. C.] Hillingdon Hosp NHS Fdn Trust, Uxbridge, Middx, England, [Kon, Samantha S. C.] Royal Brompton & Harefield NHS Fdn Trust, NIHR Resp Biomed Res Unit, London, England, [Man, William D-C] Royal Brompton & Harefield NHS Fdn Trust, NIHR Resp Biomed Res Unit, London, England, [Kon, Samantha S. C.] Imperial Coll, London, England, [Man, William D-C] Imperial Coll, London, England, [Kwon, Namhee] GlaxoSmithICline GSK, Resp Franchise Med, London, England, [Lee, Sang-Do] Univ Ulsan, Coll Med, Clin Res Ctr Chron Obstruct Airway Dis, Asan Med Ctr,Dept Pulm & Critical Care Med, Seoul, South Korea, [Locantore, Nicholas] GlaxoSmithICline, King Of Prussia, PA USA, [Lopez-Campos, Jose L.] Univ Seville, Hosp Univ Virgen Rocio, Inst Biomed Sevilla, Unidad MedQuirarg Enfermedades Resp, Seville, Spain, [Lopez-Campos, Jose L.] Inst Salud Carlos III, CIBERES, CIBER Enfermedades Resp, Madrid, Spain, [Maricic, Lana] Univ JJ Strossmayer Osijek, Fac Med, Dept Internal Med, Univ Hosp Osijek, Osijek, Croatia, [Mendoza, Laura] Hosp Clin Univ Chile, Independencia, Region Metropol, Chile, [Mihaltan, Florin] Inst Pneumol Marius Nasta, Bucharest, Romania, [Minami, Seigo] Osaka Police Hosp, Dept Resp Med, Osaka, Japan, [Nishijima, Yu] Osaka Police Hosp, Dept Resp Med, Osaka, Japan, [Ogata, Yoshitaka] Osaka Police Hosp, Dept Resp Med, Osaka, Japan, [Nishijima, Yu] Osaka Univ, Grad Sch Med, Dept Resp Med Allergy & Rheumat Dis, Suita, Osaka, Japan, [O'Donnell, Denis E.] Queens Univ & Kingston Gen Hosp, Dept Med, Kingston, ON, Canada, [Webb, Katherine A.] Queens Univ & Kingston Gen Hosp, Dept Med, Kingston, ON, Canada, [Pereira, Eanes D.] Fed Univ Ceara Brazil, Fortaleza, Ceara, Brazil, [Price, David] Observat & Pragmat Res Inst, Singapore, Singapore, [Price, David] Univ Aberdeen, Aberdeen, Scotland, [Pothirat, Chaicharn] Chiang Mai Univ, Fac Med, Dept Internal Med, Div Pulm Crit Care & Allergy, Chiang Mai, Thailand, [Raghavan, Natya] McMaster Univ, Dept Med, Hamilton, ON, Canada, [Ringbaek, Thomas] Univ Copenhagen, Hvidovre Hosp, Dept Resp Med, Copenhagen, Denmark, [Sajkov, Dimitar] Flinders Med Ctr, Australian Resp & Sleep Med Inst, Adelaide, SA, Australia, [Sigari, Naseh] Kurdistan Univ Med Sci, Med Fac, Internal Med Dept, Sanandaj, Iran, [da Silva, Guilherme F.] Univ Fortaleza, UNIFOR, Fortaleza, Ceara, Brazil, [Tsiligianni, Ioanna G.] Agia Barbara Hlth Care Ctr, Iraklion, Greece, [Tulek, Baykal] Selcuk Univ, Fac Med, Dept Chest Dis, Konya, Turkey, [Tulek, Baykal] Univ Crete, Med Sch, Univ Hosp Herakl, Dept Thorac Med, Iraklion, Greece, [Watz, Henrik] German Ctr Lung Res, Pulm Res Inst, Lung Clin Grosshansdorf, Grosshansdorf, Germany, [Xie, Guogang G.] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Resp Med, Shanghai, Peoples R China, [Spruit, Martijn A.] Hasselt Univ, Fac Med & Life Sci, Biomed Res Inst, REVAL,Rehabil Res Ctr,BIOMED, Diepenbeek, Belgium, [Spruit, Martijn A.] Maastricht Univ, Med Ctr, NUTRIM Sch Nutr & Translat Res Metab, Dept Resp Med, Maastricht, Netherlands, MRC, National Institute for Health Research, Medical Research Council, Department of Health, Medical Research Council (MRC), EU/IMI Joint Undertaking, TOBB ETU, Faculty of Science and Literature, Department of Psychology, TOBB ETÜ, Fen Edebiyat Fakültesi, Psikoloji Bölümü, Atalay, Nart Bedin, and Groningen Research Institute for Asthma and COPD (GRIAC)

Subjects
ASSESSMENT TEST SCORE, Male, clinical significance, health status, HISTORY ASSESSMENT, Global Health, Severity of Illness Index, Pulmonary Disease, Chronic Obstructive, 0302 clinical medicine, Assessment test score, Quality of life, CLINICAL CHARACTERISTICS, QUALITY-OF-LIFE, Sickness Impact Profile, 030212 general & internal medicine, Prospective cohort study, Copd assessment test, General Nursing, POPULATION, COPD, education.field_of_study, HEALTH-STATUS, COPD ASSESSMENT TEST, Evidence-Based Medicine, medicine.diagnostic_test, Health Policy, Age Factors, Cat, CAT, General Medicine, Middle Aged, Obstructive lung disease, Health-status, 3. Good health, 1117 Public Health And Health Services, Practice Guidelines as Topic, Disease Progression, Female, Symptom Assessment, Research-council scale, Spirometry, medicine.medical_specialty, Population, Risk Assessment, 03 medical and health sciences, Sex Factors, Internal medicine, Severity of illness, medicine, Humans, GOLD, education, Aged, Receiver operating characteristic, Clinical characteristics, business.industry, 1103 Clinical Sciences, medicine.disease, RESEARCH-COUNCIL SCALE, History assessment, PHYSICAL-ACTIVITY, 030228 respiratory system, Geriatrics, Physical therapy, Physical-activity, Quality-of-life, Geriatrics and Gerontology, business
Abstract

Background: Patients with chronic obstructive pulmonary disease (COPD) can be classified into groups A/C or B/D based on symptom intensity. Different threshold values for symptom questionnaires can result in misclassification and, in turn, different treatment recommendations. The primary aim was to find the best fitting cut-points for Global initiative for chronic Obstructive Lung Disease (GOLD) symptom measures, with an modified Medical Research Council dyspnea grade of 2 or higher as point of reference.Methods: After a computerized search, data from 41 cohorts and whose authors agreed to provide data were pooled. COPD studies were eligible for analyses if they included, at least age, sex, post-bronchodilator spirometry, modified Medical Research Council, and COPD Assessment Test (CAT) total scores.Main outcomes: Receiver operating characteristic curves and the Youden index were used to determine the best calibration threshold for CAT, COPD Clinical Questionnaire, and St. Georges Respiratory Questionnaire total scores. Following, GOLD A/B/C/D frequencies were calculated based on current cut-points and the newly derived cut-points.Findings: A total of 18,577 patients with COPD [72.0% male; mean age: 66.3 years (standard deviation 9.6)] were analyzed. Most patients had a moderate or severe degree of airflow limitation (GOLD spirometric grade 1, 10.9%; grade 2, 46.6%; grade 3, 32.4%; and grade 4, 10.3%). The best calibration threshold for CAT total score was 18 points, for COPD Clinical Questionnaire total score 1.9 points, and for St. Georges Respiratory Questionnaire total score 46.0 points.Conclusions: The application of these new cut-points would reclassify about one-third of the patients with COPD and, thus, would impact on individual disease management. Further validation in prospective studies of these new values are needed. (C) 2017 AMDA - The Society for Post-Acute and Long-Term Care Medicine.

Published
2017

26. Anthracosis and anthracofibrosis.

Author

Sigari N and Mohammadi S

Subjects
Anthracosis diagnosis, Anthracosis epidemiology, Bronchoscopy, Constriction, Pathologic, Female, Humans, Iran epidemiology, Male, Retrospective Studies, Risk Factors, Rural Population, Smoke, Bronchi pathology
Abstract

Objective: To define the clinical, radiographic, and bronchoscopic features, and to describe the occupations of the largest group of patients with anthracosis., Methods: All patients who underwent flexible bronchoscopy at 2 Iranian hospitals (Imam Hospital [Tehran], and Tohid Hospital [Sanandaj]), Iran, between April 1982 and June 2006 were considered for inclusion in the study. The demographic data, clinical, and radiographic findings of anthracotic and anthracofibrotic patients were recorded., Results: Of the 14,300 patients, 487 cases of simple anthracosis, and 291 of anthracofibrosis were found. A total of 98.4% female patients were housewives, and 86.4% lived in rural areas. Of the male patients, 40.6% were farmers, 29.6% were manual workers, and 7.5% were miners. Of these, 96% of patients had abnormal chest radiography. On bronchoscopic examination, bilateral bronchial involvement was found in 62.5% of the patients. The condition was confined to the trachea in 0.38% of patients, the bronchi involved were the main bronchus in 37%, the lobar bronchi in 83.2%, and segmental bronchi in 35%. Bronchial narrowing and obstruction was observed in 37.4% of the patients., Conclusion: Anthracosis and anthracofibrosis are neglected conditions that are a common finding on routine bronchoscopic examination. Given the demographic findings, and a review of other reports from developing countries, exposure to combustion of biomass fuel in rural areas is a possible risk factor.

Published
2009

27. Prevalence of asthma and rhinitis in bakery workers in the city of Sanandaj, Iran.

Author

Sigari N, Rahimi E, Yazdanpanah K, and Sharifian A

Subjects
Adolescent, Adult, Aged, 80 and over, Cross-Sectional Studies, Food-Processing Industry, Humans, Iran, Male, Middle Aged, Prevalence, Asthma epidemiology, Occupational Diseases epidemiology, Rhinitis epidemiology
Abstract

Baker's asthma is one of the most common forms of occupational asthma. This study was conducted to determine prevalence of asthma and rhinitis among bakery workers in the city of Sanandaj, the provincial center of Kurdistan province in the west of Iran in the in Summer 2006. In this study 776 bread bakery workers were included. These subjects were selected randomly among 1620 bakery workers. The diagnosis of asthma was based on a medical history of episodic symptoms of cough, chest tightness, and dyspnea and spirometry. Airflow obstruction was determined with spirometry, the definition of airflow obstruction which was used in this study was an FEV1/FVC ratio < 0.8, and FEV1 or FVC increases of > or = 12 percent and at least 200 mL after using a short-acting inhaled beta2-agonist. Rhinitis was diagnosed by typical history of work related symptoms. Analyses were performed on 776 subjects (all were men) without missing data for asthma and rhinitis. All of subjects were male with mean age of 33.69+/-11.09 years. Mean duration of bakery working for these subjects was 13.91+/-9.37 years. Prevalence of asthma at the time of study was 11.9%. 93 subjects were diagnosed as asthma with history, physical and spirometry findings. 31 (33.3%) of asthmatic workers were diagnosed as asthma previously and 62 (66.6%) workers were known as new asthmatic patients which were diagnosed in this study program. The prevalence of rhinitis was (9.9%). Subjects with asthma had longer history of working at bakery than others (P=0.001). Asthma prevalence among these bakery workers that were included in our study was similar and in some instances the prevalence was lower than other studies.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results